Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elicio Therapeutics, Inc. (ELTX : NSDQ)

• Company Description    Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $3.00 Daily Weekly Monthly 20 Day Moving Average: 1,140,540 shares Shares Outstanding: 19.09 (millions) Market Capitalization: $57.26 (millions) Beta: 1.26 52 Week High: $16.00 52 Week Low: $2.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.00% -20.59% 12 Week -71.75% -72.53% Year To Date -62.31% -63.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 451 D Street 5th Floor - Boston,MA 02210 USA ph: 857-209-0050 fax: - ir@elicio.com http://www.elicio.com

• General Corporate Information    Officers Robert Connelly - Chief Executive Officer and President Preetam Shah - Chief Financial Officer Julian Adams - Director Carol Ashe - Director Allen Nissenson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28657F103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 19.09 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.26 Market Capitalization: $57.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.29% vs. Previous Quarter: -32.65% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -2,748.16 12/31/25 - -977.66 ROA 06/30/26 - - 03/31/26 - -151.12 12/31/25 - -141.55 Current Ratio 06/30/26 - - 03/31/26 - 2.24 12/31/25 - 2.38 Quick Ratio 06/30/26 - - 03/31/26 - 2.24 12/31/25 - 2.38 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - -0.08 12/31/25 - 0.09 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - 5.75 Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - 85.18

Powered by Zacks Investment Research ©